Old Silver VC is an evergreen family-associated fund that makes early stage investments in Biotech, Digital Health, AI, and Material Sciences. We believe that the world’s greatest problems can be solved with innovative science and technology solutions. We seek and support early-stage founders with a vision that can scale from science fiction to new reality.
Michael is the Founding Partner at Old Silver VC, the Head of Search and Evaluation at Pear Therapeutics and a World Economic Forum Global Shaper.
Vice President of Business Development at a Cambridge-based cell state start up in stealth mode.
Andrew Emmons, MBA
Focuses on early-stage investments in the technology, SaaS, and healthcare industries.
Well versed in corporate development and strategic & operational excellence focusing on biotechnology and healthcare.
Corporate strategy & development at Valo Health, head of partnerships & licensing at 2 Minute Medicine, co-founder and board director at Nucleate Bio. Fund advisor specializing in translational biotechnology, AI drug discovery and platform strategy.
PhD Candidate at Stanford University researching biomaterial-based immunomodulation strategies for tissue engineering
David Paik, PhD
Instructor at Stanford Cardiovascular Institute and Stanford University School of Medicine. Current focus of research is in advancing cardiovascular precision medicine using single-cell omics and patient-specific induced pluripotent stem cell models.
Hannah Bolland, PhD
Postdoctoral researcher at Oxford University working in the field of tumour hypoxia, reactive oxygen species and development of novel fluorescent and responsive MRI probes to measure hypoxia.
Undergraduate at Princeton University researching breast cancer bone metastasis and application of scRNA-seq technology
Dartmouth Tuck MBA candidate with experience in biopharma R&D, project management, corporate and business development, and venture capital.
Lara Maggs, MBE
PhD candidate in genetics and molecular biology studying translation synthesis, a DNA damage response pathway in which specialized polymerases traverse blocking DNA lesions. Bioethicist focused on the ethical implications of germline gene editing.
Michael Trinh, PhD
MD-PhD candidate at the University of Texas Southwestern Medical Center studying cholesterol metabolism
Sunil Yadav, PhD
Postdoctoral researcher at Stanford University School of Medicine researching targeted therapies for genetic cardiomyopathies.
Tiffany Ma, MTM
PhD candidate at the University of Oxford researching strategies to target therapy-resistant tumours in solid cancers.
Senior software engineer at Microsoft whose expertise spans multiple verticals of the software engineering domains and a number of programming languages including C, C++, C# and Python.
Alicia Chong Rodriguez, MS, MSc
Femtech Catalyst, Founder & CEO at Bloomer Tech: Tailoring cardiovascular care for women via an augmented garment platform and novel digital biomarkers.
Debbie Lin, PhD
Healthtech investor is currently excited about digital health, med devices, new materials, AI and drug discovery tools.
David Mou, MBA, MD
Chief Medical Officer at Cerebral & Co-founder / former CMO of Valera Health, a venture-backed digital healthcare company.
Emilia Javorsky, MD, MPH
Physician-Scientist and former Harvard Medical School researcher focused on the development and translation of medical technologies.
Everett Crosland, MS, JD
Life sciences executive, with a proven track record commercializing and scaling complex drugs, drug-device combos, and digital therapeutics.
Co-founder of ThoughtMetric Inc- a next-generation analytics platform designed to help Mid-Market and SMB eCommerce stores better understand their customers.
Jordan Haviland, MBA
CEO of Brattle Point, LLC, where he focuses on acquiring growing technology and service businesses in scientific and industrial markets.
Livio Valenti, MPP
Sustainability entrepreneur and co-founder of Vaxess Technologies, a biotechnology company reimagining vaccine delivery.
Liz Kwo, MD, MBA, MPH
Deputy Chief Clinical Officer at Anthem & Co-Founder / former CEO of InfiniteMD.
Louis Kang, PhD
Managing Director at AccelR8, Co-Founder at MitoLab, Venture Partner at Korea Technology Bank (KTB) VC
M.D. candidate at the Perelman School of Medicine passionate about innovation in biotech, digital health, and health equity.
Head of Bio & Deep Tech at BoxOne Ventures, Venture Partner at Entrepreneur First, and active angel investor. A neuroscientist by training, turned entrepreneur, and active investor. Appointed as a Strategic Advisor to LifeOmic, and as an External Advisor to AstraZeneca.
Founding Partner at First Star Ventures, an early-stage venture fund focuses on cutting edge data technologies.
Partner at Arkitekt Ventures
Rebecca Maynard, LLM, JD
Compliance & Privacy Specialist at Boston Children's Hospital
Head of CX at NLP startup Forethought.ai, winner of TechCrunch Disrupt and funded by NEA, Village Global, K9 Ventures, etc.
Ryan Coles, MS, PHD
Assistant Professor of Entrepreneurial Management at UConn's School of Business, and the Chief Science Officer at Human Wealth.
Sean Cheng, MP, PHD
Early stage investor in health tech companies and is currently excited about digital therapeutics, remote patient care, novel devices, and disruptive enablers.
Sophie Bai, MBA
Founder and CEO of a biotech company using novel transdermal drug delivery technologies to get large molecules into the skin.
Zack Gow, ME, MS
Data scientist, machine learning engineer, and entrepreneur.
Freddie Martignetti, MBA
Investor at Highland Capital Partners, a global leader in early stage consumer and enterprise technology investments.
Robert Langer, Sc. D
Dr. Langer is one of 10 Institute professors at MIT (MITs highest honor). He is an expert in the fields of tissue engineering and drug delivery and has founded over 40 startup companies. He is the most cited engineer in history.
Prior Investments or Early Shareholder Positions